The EPS miss and accelerating cash burn are near-term negatives, but the upcoming FURVENT data readout (2H 2026) is the primary catalyst. Traders should watch for pre-data positioning; a positive Phase 3 result could offset current financial weakness. Cash runway into 2028 reduces near-term dilution risk.
Price Chart
Executive Summary
ArriVent reported Q2 2026 EPS of -$1.05, a 16.7% miss vs consensus of -$0.98, with net loss widening to $49.9M from $31.4M a year ago. The company highlighted upcoming pivotal Phase 3 data for firmonertinib in 2H 2026 and ADC pipeline progress, but the EPS miss and rising R&D spend ($42.3M vs $27.7M) signal accelerating cash burn. Cash runway into 2028 provides a buffer, but the lack of revenue and deepening losses make this a bearish read-through for a pre-commercial biotech.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$1.05 missed consensus of -$0.98 by 7.1%
- Net loss widened to $49.9M from $31.4M in Q2 2025
- R&D expenses rose 52.7% YoY to $42.3M
- Cash and investments of $373.1M expected to fund operations into 2028
- Top-line data from FURVENT Phase 3 study for firmonertinib expected 2H 2026
- ARR-217 ADC advanced to Phase 1b dose optimization; ARR-002 IND cleared
Financial Impact
EPS miss of $0.07 per share; net loss increase of $18.5M vs prior year quarter
Risk Factors
- FURVENT Phase 3 data may fail to meet endpoints, wiping out pipeline value
- Cash burn rate is accelerating with no revenue, risking future dilution
- ADC pipeline (ARR-217, ARR-002) is early-stage with high failure risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344035 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $23.64 | awaiting T+5 | — | $14.86 (−37.14%) |
Oct 25, 2026 1d ago | Press Release | $21.00 | awaiting T+5 | — | $14.86 (−29.24%) |
Oct 23, 2026 2d ago | Press Release | $21.00 | awaiting T+5 | — | $14.86 (−29.24%) |
Oct 19, 2026 7d ago | 8-K | $17.94 | awaiting T+5 | — | $14.86 (−17.17%) |
Oct 13, 2026 12d ago | SC 13G | $16.20 $19.12 | ▲ +18.02% | ▲ +17.57% | $14.86 (−8.27%) |
Oct 13, 2026 13d ago | 8-K | $16.09 $18.85 | ▲ +17.15% | ▲ +18.31% | $14.86 (−7.64%) |
Oct 8, 2026 17d ago | SC 13D/A | $16.73 $16.66 | ▲ +0.42% | ▼ −1.55% | $14.86 (+11.18%) |
Oct 6, 2026 20d ago | 8-K | $15.09 $16.09 | ▼ −6.63% | ▼ −6.77% | $14.86 (+1.52%) |
Aug 12, 2026 10w ago | Press Release | $30.00 $29.18 | ▲ +2.73% | ▲ +0.77% | $14.86 (+50.47%) |
Jun 11, 2026 19w ago | Institutional Cluster | $30.54 $31.74 | ▲ +3.93% | ▲ +3.26% | $14.86 (−51.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers